Ring Therapeutics
- Founded: 2017
- Location: Cambridge, MA
- Employee range: 11 - 50
- Funding: $86.5M C Mar 2023; $117M B Jul 2021; $50M Dec 2019
- Investors: Flagship Pioneering, Alexandria Venture Investments, Altitude Life Science Ventures, CJ Investment, Invus, Kyowa Kirin Co., Ltd
ringtx.com linkedin.com job board
Short description:
Gene Therapy Targeting the Human Commensal Virome
Drug notes:
Contact us to add description: recruit@workinbiotech.com
Long description:
Ring Therapeutics is a biotech company developing gene therapies called Anellovector therapeutics. Anellovectors are derived from naturally occurring commensal anelloviruses, which are viruses that live in the human body without causing harm. Ring Therapeutics believes that anellovectors have the potential to overcome the limitations of traditional gene therapies, such as limited breadth, an inability to redose, and poor tolerability. Ring Therapeutics' lead product candidate is Anellovector-CD34, which is being developed for the treatment of sickle cell disease. Anellovector-CD34 is designed to deliver a gene that codes for a protein that helps to prevent the sickling of red blood cells. Ring Therapeutics is also developing Anellovector-CAR T cells, which are a type of gene therapy that uses the patient's own immune cells to fight cancer.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com